1 Mechanism-based model of effect of co- administration of exogenous testosterone and progestogens on the hypogonadal axis in men Ashley Strougo (1), Jeroen.

Slides:



Advertisements
Similar presentations
Informationsteknologi Institutionen för informationsteknologi | State estimation in endocrine systems with pulsatile hormone secretion Alexander.
Advertisements

Hormonal Control of Male Reproductive Functions Hormones are secreted by: – Hypothalamus – Anterior pituitary gland – Testes Functions: – Development of.
Androgen metabolism Kieran Jefferson. Testosterone SMOOTH ENDOPLASMIC RETICULUM Cholesterol Pregnenolone Testosterone Progesterone 17  -OH- Progesterone.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.
Male Reproductive Function Anatomy Hormonal Control Pathophysiology.
Aging of the Male Reproductive System Spring 2007 PS Timiras.
Local and systemic control of gonadal function. Human: 1 oocyte – 150 million sperm.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Male Reproductive System
Hormonal control of Reproduction
Gonad Hormones : Male Prof.Dr.Gülden Burçak
The Male Reproductive System
Resident Research: Andrology topics Ada Lee, PGY2 Chief of Medicine Rounds 3/22/11.
Endocrinology... The Study of Hormones Today's Warm-up: Name one thing you think hormones are responsible for doing in your body.
Reproductive Physiology Lecture 1 Hypothalamic-Pituitary-Gonadal axis.
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
BIOLOGICAL MODELS International Science Forum on Computational Toxicology May 21–23, 2007 Research Triangle Park, North Carolina Hugh A. Barton 1, Laura.
Background Objectives Data Simulation in human Conclusion -F14512, a polyamine-vectorized anti-cancer drug which combines an epipodophyllotoxin core targeting.
Reproductive Hormones Gonads Source of sex hormones: androgens estrogens progestins produced in different proportions by both males and females.
Luteal coasting post GnRH agonist trigger
PowerPoint ® Lecture Slides prepared by Janice Meeking, Mount Royal College C H A P T E R Copyright © 2010 Pearson Education, Inc. 27 The Male Reproductive.
BioSciences eOWYOFoAhttps:// eOWYOFoA.
Reproductive System Section 1 Reproductive and Hormonal Functions of the Male Section 2. Reproductive and Hormonal Functions of the Female Section 3. Hormonal.
MECHANISTIC MODEL OF STEROIDOGENESIS IN FISH OVARIES TO PREDICT BIOCHEMICAL RESPONSE TO ENDOCRINE ACTIVE CHEMICALS Michael S. Breen, 1 Miyuki Breen, 2.
Model structure  Law of mass action applied to describe the reversible solifenacin-AGP, solifenacin-albumin and solifenacin-VBC binding  VBC positioned.
9.4 Hormonal Regulation of the Reproductive System
LOGO Reproductive System YaoYang, Physiology department of SMC.
Model-based dose selection for next dose- finding trial 1. Introduction Exploratory clinical development trials often include biomarkers or clinical readout.
Background Sexual Interests and Hypogonadism in Prader-Willi Syndrome Harry J Hirsch 1, Talia Eldar-Geva 2, Fortu Benarroch 3, Orit Rubinstein 1, and Varda.
HORMONES OF THE GONADS. The gonads are bifunctional organs that produce germ cells and the sex hormones. The ovaries produce ova and the steroid hormones.
A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.
Ezetimibe Overall Conclusions
Disrupting Hormones What hormones are involved in reproduction?
Colorado Agriscience Curriculum Animal Science Unit 4- Reproduction and Genetics Lesson 3 Male Hormones of Reproduction.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
GnRH Agonists Alter Body Composition After Long Term Exposure Grace Shearrer, (Brian S. Edwards, Arik W. Smith and Donal C. Skinner)
+ Hormones of the Male Reproductive System Robin Gottschalk BIO 260 Professor Tonini December 9, 2015.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
1 Centchroman ® Key Features of a Nonhormonal Contraceptive Pill.
The Reproductive System. Review of Endocrine System.
Hormonal Regulation of Male Reproductive Function
Abstract Results Effects of Iron Therapy on Pituitary Gonadal Axis and Sperm Parameters in Adults with Iron Deficiency Anemia (IDA). Ashraf T. Soliman,
Reproductive and Hormonal Functions of the Male: After studying this lecture you should understand: (1)spermatogenesis, which means simply the formation.
Chapter 46.4 and 46.5 Animal Reproduction.
UOG Journal Club: February 2016
Hormones of Testes - Testosterone Lecture NO: 2nd MBBS
The Reproductive System
HORMONES OF THE GONADS.
Male hypogonadism.
Figure 1 The hypothalamic–pituitary–gonadal axis
Reproductive Hormones
Effects of chronic exposure to a high dose GnRH agonist (Deslorelin)
Figure 1. Effect of neonatal treatment with vehicle (Control), DES (10 μg), Bis-A, or OP; maintenance of rats on a soy-free diet (SF control); or the administration.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Figure 1. TAK-448 structure (A) and effect on the hypothalamic-pituitary-gonadal axis (B). At the normal physiological state, GnRH pulses in the hypothalamus.
6.6 Hormones, homeostasis and reproduction
Lecture 1 Hypothalamic and pituitary gonadal axis
Reproduction and Development
Hormonal Regulation of the Reproductive System
A – The reproductive system
Hormonal Control of Reproductive Tract Function
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
A – The reproductive system
Male contraception Fertility and Sterility
Longitudinal Analysis Beyond effect size
Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency  Carrie.
Male Reproductive System Review
Regulation of the Reproductive System
Maximum mean (SE) per cent change in serum urate from baseline (Emax) following once-daily oral administration of varying verinurad doses in combination.
Fig. 1. Image explaining the contraceptive effect of exogenous testosterone. In summary, it works by 2 mechanisms, decreasing intra-testicular testosterone,
Presentation transcript:

1 Mechanism-based model of effect of co- administration of exogenous testosterone and progestogens on the hypogonadal axis in men Ashley Strougo (1), Jeroen Elassais-Schaap (2) Rik de Greef (2), Henk-Jan Drenth (1) PAGE 2007, København, Denmark 13 June 2007 (1) LAP&P Consultants BV (2) PK-PD / M&S, Clinical Pharmacology &Kinetics, Organon

2 Aim Development of a mechanism-based model of the homeostatic feedback relationships in the endocrinology of the male reproductive system Modeling of the endocrinological effects following co-administration of testosterone and progestogens (“male pill”) Prediction of the effects of newly developed androgens plus progestogens on spermatogenesis

3 Study data 5 clinical trials 288 healthy male volunteers Treatment period: 1 ½ weeks up to 48 weeks Treatment medications: Progestogen alone DSG: p.o (daily) Progestogen plus testosterone DSG/ENG: p.o (daily), s.c (once) TD/TE: i.m. (once/week, once/4 weeks, once/6 weeks) Baseline Treatment Wash out

4 Endocrine regulation of the male reproductive system Brain LHFSH Lydig cells Sertoli cells Testes T - inhibin - - GnRH + Hypotalamus Anterior pituitary exogenous T progestogen T

5 Model structure baseline only T T LH FSH Kin kout Kin kout - - +

6 Model structure DSG only T T LH FSH Kin kout Kin kout DSG

7 Model structure DSG/ENG plus TD/TE exogenous T dLH/dt = Kin LH. 1/T. (1-Effect LH ) – kout LH. LH dFSH/dt = Kin FSH. 1/T. (1-Effect FSH ) – kout FSH. FSH dT/dt = k infusion T + Kin T.LH – kout T.T T T LH FSH Kin kout Kin kout DSG / ENG

8 Visual predictive checks (1) Brady et al, 2006 baseline 1-4 weeks 1 measurement 48 weeks32 weeks ENG implant (day 1) washout LH FSH T mg TD / 6 weeks

9 Visual predictive checks (2) Wu et al, 1999 baseline 1-4 weeks 1-2 measurements 22 days20 weeks24 weeks 300 ug DSG o.d. washout FSH T. LH.. 50 mg TE / week

10 Summary results Adequate description of the time courses of LH, FSH and T after administration of DSG alone or DSG/ENG plus TE/TD: TD formulation: T not immediately in steady state, resulting in slight bias Co-administration of ENG/DSG with TD/TE: adequate predictions when effect of ENG/DSG on LH and FSH is amplified Good prediction of steady-state situations (baseline, treatment period and washout) Parameters were well estimated (CV < 12%*) Kout’s fixed at stage 2 of model development * except for the parameter that describes the effect after administration of DSG only (CV=68%)

11 Model applicability in drug development Prediction of the effect of newly developed androgens plus progestogen : Assumptions: (i) the androgen is twice as potent as T; (ii) azoospermia is achieved when LH and FSH concentrations are below 0.5 U/L. T T LH FSH Kin kout Kin kout Androgen Kinfusionke

12 Model applicability in drug development Prediction of the effect of newly developed androgens : Androgen steady state concentrations of 0.3 nmol/L is required

13 Conclusions & future applications Achieved: Integrated model of the major endocrine relationships of the male reproductive system Separately accounts for the effect of progestogen and progestogen plus exogenous testosterone Sound basis for further mechanistic refinement Possible future applications: by combining the data of T, LH and FSH, and making use of existent knowledge of the endocrinology of the male system this model allows: Prediction of the effect of newly developed androgens Elucidation of underlying mechanisms Further development and refinement: Inclusion of the contraceptive effect in the model (i.e. sperm-count)

14 Acknowledgments

15

16 Back up slides

17 Study data Trial publicationNo. of subjTreat. periodTreatment not published9 1 ½ weeks (10 days) 300 µg DSG (o.d.) Cathy et al, weeks 300 µg ENG (o.d.) mg TD (once/4 weeks) 300 µg ENG (o.d.) mg TD (once/6 weeks) Brady et ai, weeks ENG implants (once) mg TD (once/4 weeks) ENG implants (once) mg TD (once/6 weeks) ENG implants (once) mg TD (once/6 weeks) Wu et al, 1999*2424 weeks 300 µg DSG (o.d.) mg TE (once a week) 300 µg DSG (o.d.) + 50 mg TE (once a week) 150 µg DSG (o.d.) mg TE (once a week) Anawalt et al, weeks 300 µg DSG (o.d.) mg TE (once a week) 150 µg DSG (o.d.) mg TE (once a week) 150 µg DSG (o.d.) + 50 mg TE (once a week) Baseline Treatment Wash out

18 Individual plots Wu et al, 1999 : Dose TE: 50 mg/week; Dose DSG:300 ug

19 Model applicability in drug development (2) Elucidation of underlying mechanisms: Hypothesis: inhibition of SHBG concentrations would partly justify the greater Effect LH and Effect FSH extent after co-administration of T and progestogen. T T LH FSH Kin kout Kin kout SHBG Kin kout Kinf T +

20 Elucidation of underlying mechanisms: Inhibition of SHBG concentrations partially justified the amplified progesterone effect on LH and FSH Model applicability in drug development (2)

21 Effect of T on LH and FSH (check assumption) WHO, 1996 Dose TE: 200 mg/week Further mechanistic refinement dLH/dt = Kin LH. 1/T. (1-Effect LH ) – kout LH. LH dFSH/dt = Kin FSH. 1/T. (1-Effect FSH ) – kout FSH. FSH